Abstract:
Introduction: Tuberculosis (TB) is a major cause of morbidity and mortality worldwide especially in developing countries like Ethiopia. Tuberculosis treatment outcome is one of the important issues to reduce this high mortality and morbidity.
Objective:The goal of this research is to assess TB treatment outcome and its associated factors among TB patients attending in Bahir Dar town governmental health institutions.
Methods: A five years retrospectivefollow study wasconducted among TB patients in Bahir Dar town governmental health institutions.Among ten health centers four health centers were selected by using multi stage sampling technique and one hospital was taken thenSimple random sampling technique was used to select the registered patients. Structured checklistwas used to collect the data from the TB registration book. Training was given for two data collectors and close supervision was made by the principal investigator. Data were entered in to EPI Info and exported toSPSS version 20 software for analysis. Descriptive statistics was used to summarize the data. Bivariate and Multivariate logistic regression model were used. Crude and Adjusted odds ratio with 95% CI interval were used to assess the strength of association between the outcome and independent variables.
Result:A total of 416 TB patients were participated in the study. More than half 240 (57.5 %) of the participants were males and two third 284 (68.3%) were urban dwellers. The mean age of the participants was 28.55 (SD14.9) years. Poor TB treatment outcome was 41 (9.9%) (95% CI: 7.0, 13.1%). Out of patients with poor outcome,28(68.3%) were died, 9 (22.0%) had treatmentfailure and 4 (9.8%) were loss to follow up.HIV positive TB patients were (AOR=5.1 (95% CI: 2.6, 10.1) significantly associated with poor treatment outcome.
Conclusion and Recommendation:Poor TB treatment outcome among TB patients was found to be high. HIV status was identified to be the associated factors for poor TB treatment outcome. Hence, special attention has to be given for TB/HIV co-infected patients to enhance good treatment outcome.